On September 10th, Bangkai joined a delegation of 15 companies, including the Shandong Pharmaceutical Association, Shandong Institute of Industry and Information Technology, Pharmaceutical Industrial Design Institute, Xinhua Pharmaceutical, Lukang Pharmaceutical, Shuanghe Limin, Xinhua Medical, Ruiyang Pharmaceutical, and Jingwei Pharmaceutical, on a four-day study and exchange trip to Zhejiang. Jiang Jufang, Executive President of the Zhejiang Pharmaceutical Association, warmly welcomed and accompanied the delegation throughout the trip. The event aimed to strengthen exchanges and cooperation between the pharmaceutical industries of Shandong and Zhejiang, learn from the advanced experience of Zhejiang's pharmaceutical industry, and jointly explore industry development and cooperation.

With the goal of promoting cross-regional collaborative development of the pharmaceutical industry and strengthening upstream and downstream collaboration, the delegation visited renowned companies such as Betta Pharmaceuticals, Minsheng Pharmaceutical Holding Group, Hu Qingyu Tang, New Hope Group, and Zhejiang Medicine, as well as the Zhejiang Pharmaceutical Industry Association. Through on-site visits and discussions, they gained a deeper understanding of Zhejiang's pharmaceutical industry development experience and innovative models.

At Betta Pharmaceuticals, Bangkai accompanied the delegation to visit the company's R&D center and production lines, and learned in detail about its achievements in innovative drug research and development and industrialization; Minsheng Pharmaceutical Holding Group's practice of combining pharmaceutical craftsmanship with innovative development provided us with valuable reference; Hu Qingyu Tang, a century-old traditional Chinese medicine company, demonstrated the cultural heritage and inheritance of traditional Chinese medicine. Its "anti-fraud" culture and development concept of fine Chinese medicine were deeply inspiring; New Hope Group and Zhejiang Medicine, as representative companies in the integrated development of raw materials and preparations, their experience in industrial chain layout and international market development provided useful reference for many Shandong companies including Bangkai.

This exchange and study trip to Zhejiang not only provided Bangkai with a valuable opportunity to gain market insights and understand industry trends, but also provided important insights for the company's scientific development of its 15th Five-Year Plan. Through this exchange and study, Bangkai has established channels for communication and learning with several pharmaceutical companies in Zhejiang, laying a solid foundation for future in-depth cooperation. The company will use this exchange as an opportunity to further strengthen its collaboration with Zhejiang pharmaceutical companies in areas such as technological innovation and product application, jointly promoting the research and development and innovation of new silica materials in the pharmaceutical industry, and injecting new impetus into the high-quality development of the pharmaceutical industry.